Note 18 - Segments

12 Months Ended

Dec. 31, 2023

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

Note 18 Segments

We manage our operations in two reportable segments, pharmaceuticals and diagnostics. The pharmaceuticals segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:

	For the years ended December 31,
(In thousands)	2023			2022			2021
Revenue from services:
Pharmaceutical	$	—		$	—		$	—
Diagnostics		515,275			755,630			1,607,106
Corporate		—			—			—
	$	515,275		$	755,630		$	1,607,106
Revenue from products:
Pharmaceutical	$	167,557		$	142,845		$	141,770
Diagnostics		—			—			—
Corporate		—			—			—
	$	167,557		$	142,845		$	141,770
Revenue from transfer of intellectual property and other:
Pharmaceutical	$	180,663		$	105,721		$	25,842
Diagnostics		—			—			—
Corporate		—			—			—
	$	180,663		$	105,721		$	25,842
Operating income (loss):
Pharmaceutical	$	41,184		$	(12,961	)	$	(19,051	)
Diagnostics		(155,596	)		(173,652	)		98,067
Corporate		(42,609	)		(39,640	)		(60,266	)
	$	(157,021	)	$	(226,253	)	$	18,750
Depreciation and amortization:
Pharmaceutical	$	71,548		$	68,618		$	26,427
Diagnostics		33,749			40,037			52,289
Corporate		—			—			—
	$	105,297		$	108,655		$	78,716
Loss from investment in investees:
Pharmaceutical	$	(107	)	$	(383	)	$	(629	)
Diagnostics		—			—			—
Corporate		—			—			—
	$	(107	)	$	(383	)	$	(629	)
Revenues:
U.S.	$	597,822		$	783,207		$	1,640,354
Ireland		141,465			117,214			32,809
Chile		68,491			62,044			63,798
Spain		23,517			22,477			22,682
Israel		9,738			3,845			3,563
Mexico		20,216			14,546			11,005
Other		2,246			863			507
	$	863,495		$	1,004,196		$	1,774,718

(In thousands)	December 31, 2023		December 31, 2022
Assets:
Pharmaceutical	$	1,331,764	$	1,322,531
Diagnostics		630,753		690,504
Corporate		49,181		154,224
	$	2,011,698	$	2,167,259
Goodwill:
Pharmaceutical	$	315,235	$	312,826
Diagnostics		283,025		283,025
	$	598,260	$	595,851

No customer represented more than 10% of our total consolidated revenue during the years ended December 31, 2023, 2022 and 2021. As of December 31, 2023 and 2022, no customer represented more than 10% of our accounts receivable balance.

The following table reconciles our Property, plant and equipment, net between U.S. and foreign jurisdictions: 

(In thousands)	December 31, 2023		December 31, 2022
PP&E:
U.S.	$	39,852	$	52,795
Foreign		35,577		30,084
Total	$	75,429	$	82,879